# Dan Hicklin

> Dan Hicklin is a venture - series unknown investor at MPM Capital backing Biopharma. See 1 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [MPM Capital](https://shizune.co/investors/profile/mpm-capital)
- Location: Cambridge, United States
- Total investments: 1
- Last investment: Mar 2016
- Lead investor: 100%
- Last updated: Sep 2026

Dan Hicklin is a venture - series unknown investor at MPM Capital in Cambridge focused on Biopharma and Therapeutics. Dan Hicklin, Ph.D., joined MPM in 2014 subsequent to his successful role as President & Chief Scientific Officer and member of the Board of CoStim Pharmaceuticals (acquired by Novartis:NVS). He now serves as President and CEO of Potenza Therapeutics, an immuno-oncology company founded by MPM. Dan is also a board member of Tizona Therapeuticsand Harpoon Therapeutics, two MPM portfolio companies.

## Contacts

5 contacts available for Dan Hicklin: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/dan-hicklin?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Potenza Therapeutics | Potenza Therapeutics, Inc. is a preclinical-stage biotechnology company focused on building a portfolio of oncology programs that utilize the body’s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms that influence tumor immunity. It was founded in 2014 and headquartered in Cambridge, Massachusetts. | $30M | Venture - Series Unknown | Mar 17, 2016 |  |

1 of 1 investments shown.

## Co-investors
- [InterWest Partners](https://shizune.co/investors/profile/interwest-partners) — VC Fund, 1 deal together

## About MPM Capital

VC Fund · Cambridge, United States

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

5 contacts available at MPM Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Hicklin | Managing Director | https://shizune.co/investors/profile/dan-hicklin |
| David P. Ryan | Medical and Scientific Advisor | https://shizune.co/investors/profile/david-p-ryan |
| Detlev Biniszkiewicz | Executive Partner | https://shizune.co/investors/profile/detlev-biniszkiewicz |
| Patrick Baeuerle | Excutive Partner | https://shizune.co/investors/profile/patrick-baeuerle |
| Uciane Scarlett | Principal | https://shizune.co/investors/profile/uciane-scarlett |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## FAQ

### What does Dan Hicklin invest in?

Dan Hicklin invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Venture - Series Unknown stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Dan Hicklin?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Dan Hicklin last invest?

The most recent investment recorded for Dan Hicklin closed in Mar 2016. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co